Aurinia Pharmaceuticals (AUPH) Free Cash Flow (2020 - 2026)

Aurinia Pharmaceuticals (AUPH) has 7 years of Free Cash Flow data on file, last reported at $32.5 million in Q1 2026.

• Quarterly Free Cash Flow rose 2434.76% year-over-year to $32.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $167.6 million (up 160.64% YoY) and the FY2025 annual result came in at $136.4 million, up 207.05% from the prior year.
• Free Cash Flow declined to $32.5 million in Q1 2026, from $45.7 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $45.7 million in Q4 2025 to a low of -$46.8 million in Q1 2022.
• A 5-year average of $5.9 million and a median of $10.2 million in 2022 frame the typical range for Free Cash Flow.
• Annual changes were most pronounced in 2022 — Free Cash Flow gained 12.17% — and 2026, when it surged 2434.76%.
• Tracing AUPH's Free Cash Flow over 5 years: stood at $10.2 million in 2022, then jumped by 43.63% to $14.7 million in 2023, then jumped by 104.94% to $30.2 million in 2024, then soared by 51.43% to $45.7 million in 2025, then slipped by 28.79% to $32.5 million in 2026.
• The last three Free Cash Flow figures came in at $32.5 million (Q1 2026), $45.7 million (Q4 2025), and $44.4 million (Q3 2025), per Business Quant data.